![]() ![]() Results from a Phase 2 trial in previously vaccinated subjects has confirmed the ability of ABNCoV2 to significantly boost antibody titers to levels reported to be highly efficacious (>90%) against SARS-CoV-2, including variants of concern.Ī global Phase 3 trial assessing the non-inferiority of ABNCoV2 compared to Comirnaty ® in terms of neutralizing antibodies against the SARS-CoV-2 index virus was initiated in September 2022. Bavarian Nordic has licensed the global commercialization rights to the vaccine and has assumed the responsibility for further clinical development towards licensure.ĪBNCoV2 has shown to be highly immunogenic in relevant preclinical models inducing a durable and highly protective response from a COVID-19 challenge. ![]() We look forward to generating further data in the ongoing Phase 3 trial that will shortly open sites in Denmark.”ĪBNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac, Denmark, using their proprietary capsid virus like particle (cVLP) technology. These latest data further support the concept that ABNCoV2 could be a universal booster vaccine inducing strong and durable immune responses against all major variants of concern, including Omicron, without the need to modify the vaccine. Paul Chaplin, President and CEO of Bavarian Nordic said: “It is highly encouraging that the strong booster responses we have reported for ABNCoV2 against all variants of concern are maintained after six months post vaccination at levels associated with a high degree of efficacy. This represented less than a 50% decline in the peak neutralizing titers after six months and compared to the data published for mRNA vaccines 2,3,4, the antibody decay appears less sharp, indicating a potentially longer duration of protection across variants of concern. Six months post vaccination, neutralization titers were six times higher than pre-boost titers against Wuhan and nearly 10 times higher than the pre-boost titers for Omicron BA.1. From this cohort, two subjects with confirmed COVID-19 disease were excluded from the immune analysis. ![]() Previously reported results from the trial showed, that vaccination with 100ug ABNCoV2 in 103 seropositive subjects was able to demonstrate a strong boosting effect, increasing the existing levels of SARS-CoV-2 neutralizing antibodies against both the Wuhan variant and variants of concern (Alpha, Beta, Delta and Omicron) to levels reported to be highly efficacious (>90%) against SARS-CoV-2 1.Ī cohort of 41 subjects were followed for six months post vaccination. Six months post the booster vaccination with ABNCoV2, the neutralization antibody titers against Wuhan and the Omicron variant remained high and at levels associated with a greater than 90% efficacy.ĬOPENHAGEN, Denmark I OctoI Bavarian Nordic A/S (OMX: BAVA) announced today the results of a six-month follow-up analysis from a Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |